These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30327255)

  • 1. Drug Policy in the Russian Federation.
    Holownia-Voloskova M; Vorobiev PA; Grinin M; Davydovskaya MV; Ermolaeva TN; Kokushkin KA
    Value Health Reg Issues; 2018 Sep; 16():106-111. PubMed ID: 30327255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Policy in Greece.
    Yfantopoulos JN; Chantzaras A
    Value Health Reg Issues; 2018 Sep; 16():66-73. PubMed ID: 30195093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Policy in Romania.
    Radu CP; Pana BC; Furtunescu FL
    Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Policy in Latvia.
    Silins J; Szkultecka-Dębek M
    Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Policy in Bulgaria.
    Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
    Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Policy in Poland.
    Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
    Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
    Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug Policy in Slovakia.
    Bucek Psenkova M; Visnansky M; Mackovicova S; Tomek D
    Value Health Reg Issues; 2017 Sep; 13():44-49. PubMed ID: 29073987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Policy in Estonia.
    Mägi K; Lepaste M; Szkultecka-Dębek M
    Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization Approach for Estimating the Required Amount of Pharmaceuticals in the Russian Federation.
    Prasolov AV; Kolbin AS; Balykina YE
    Value Health Reg Issues; 2018 Sep; 16():39-45. PubMed ID: 29933241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CURRENT ENVIRONMENT FOR INTRODUCING HEALTH TECHNOLOGY ASSESSMENT IN GREECE.
    Kani C; Kourafalos V; Litsa P
    Int J Technol Assess Health Care; 2017 Jan; 33(3):396-401. PubMed ID: 28756795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
    Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
    Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Policy in Hungary.
    Inotai A; Csanádi M; Harsányi A; Németh B
    Value Health Reg Issues; 2017 Sep; 13():16-22. PubMed ID: 29073982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
    Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
    Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders.
    Wasir R; Irawati S; Makady A; Postma M; Goettsch W; Feenstra T; Buskens E
    PLoS One; 2019; 14(11):e0225626. PubMed ID: 31774854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
    Beletsi A; Koutrafouri V; Karampli E; Pavi E
    Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment.
    Drummond M; Jönsson B; Rutten F; Stargardt T
    Eur J Health Econ; 2011 Jun; 12(3):263-71. PubMed ID: 20803050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.